Vol. 18/No. 17 | OncologyLive

AKT Inhibitor May Promote Better Responses to Abiraterone in mCRPC

September 07, 2017

Ipatasertib is being investigated in patients with metastatic castration-resistant prostate cancer as a method of simultaneously blocking a resistance mechanism to hormone therapy and improving responses to abiraterone.

There's a Growing Need to Look Under the Hood of the Clinical Trial Model

August 30, 2017

The decades-long argument over whether zinc lozenges can shorten the duration of the common cold is far removed from the arena of cancer medicine, yet the studies conducted to settle the debate help illustrate the shortcomings of the clinical trial model that has dominated the oncology sphere.